Biosan Medical to Present at Medtech Insight and Windover Information's ``Investment in Innovation (In3) West'' Conference, February 23-24, 2006, Irvine, CA.

IRVINE, Calif. -- Biosan Medical has announced that it will be presenting on Thursday, February 23rd, at 4:05 p.m. at Medtech Insight and Windhover Information's "Investment in Innovation (In3) West: A Preview of Early-Stage Medical Technology Companies" Conference, February 23-24, 2006, at the Hyatt Regency Irvine in Irvine, California.

Biosan Medical is a young Israeli private medical start-up that devotes all its efforts to the development of medical device and method specifically geared for the treatment of the most deadly type of Stroke -- Subarachnoid and Intraventricular Hemorrhages of different etiologies.

10 to 15% of all 700,000 stroke cases in the U.S. each year suffer from IVH, and SAH -- Hemorrhagic Strokes -- according to 2005 American Heart Association statistical data report, resulting in over 50% mortality and staggering $7 billion direct and indirect medical costs in these types of disease alone with $17 billion worldwide.

During a brain Hemorrhagic stroke ELPE(R) (Erythrocytes Lytic Poisonous Elements) develop, causing severe Aseptic Meningitis, Hyperthermia, severe Cerebral Vascular Spasm and can bring a secondary brain Infarct.

It is of vital importance therefore to speed up the brain CSF drainage and cleaning process and remove all products of ELPE(R). This purification of the CSF from blood medical procedure is in use today by neurosurgical clinics and lasts between 2-4 weeks, during such time the ELPE (R) effects recurrent vascular spasm, and in cases of a massive SAH and ICH it can last up to 2 months.

Biosan Medical is an Israeli medical start-up headed by Dr. David Michaeli, senior neurosurgeon and a prominent scientist -- the inventor of the world's first MRI system -- and his partner, Mr. Ofer Taran, an electronics engineer, marketing specialist and entrepreneur.

Biosan Medical is the developer of Ventritek 105(R) -- a novel, patented surgical device and method for treatment of Stroke / Subarachnoid & Intraventricular and Intracerebral Hemorrhages of different etiologies. Biosan Medical's Ventritek 105(R) method and device, offers the medical neurosurgical world a revolutionary induction of purified CSF from blood back to the sick person's ventricles.

The system, in contrast to the current long, risky procedure, will decrease the patient recovery time during ventricular drainage process by 2/3, as well as dramatically minimize patient suffering and risks of developing post SAH Hydrocephalus and Cerebral Vascular Spasm, while offering huge cuts in medical costs.

Biosan Medical is seeking an equity seed money investment partner to allow it to complete its system development, improve the project financial structure and commence product marketing over a two-year period. Biosan Medical will positively consider moving its operation abroad to become a local U.S. business entity in a move to help speed up the project business decision.

A division of Windhover Information Inc., Medtech Insight is the leading provider of business information and market intelligence for the medical technology marketplace. In3 WEST is Medtech Insight's 20th investment and partnering event to date. To register to attend or for more information on Medtech Insight, please call Kristy Grimes at 480-985-9512 or 888-202-5939 toll-free in the U.S., e-mail [e-mail], or visit www.medtechinsight.com.